2020 年第 12 期 第 15 卷

来那度胺联合利妥昔单抗治疗老年复发弥漫大B细胞淋巴瘤的效果及安全性观察

Effect and safety of lenalidomide combined with rituximab in the treatment of elderly patients with recurrent diffuse large B cell lymphoma 

作者：梁瑞华1王兮1杨峰1丁利芳2

英文作者：Liang Ruihua1 Wang Xi1 Yang Feng1 Ding Lifang2

单位：1内蒙古自治区包头市肿瘤医院淋巴乳腺肿瘤内科014030；2内蒙古包钢医院肿瘤内科，内蒙古自治区包头市014030

英文单位：1Department of Lymphatic and Breast Cancer Baotou Cancer Hospital Inner Mongolia Autonomous Region Baotou 014030 China; 2Department of Oncology Inner Mongolia Baogang Hospital Inner Mongolia Autonomous Region Baotou 014030 China

关键词：弥漫大B细胞淋巴瘤；来那度胺；利妥昔单抗；疗效；安全性

英文关键词：DiffuselargeBcelllymphoma;Lenalidomide;Rituximab;Curativeefficacy;Safety 

• 摘要：

• 目的 观察来那度胺联合利妥昔单抗治疗老年复发弥漫大B细胞淋巴瘤的效果及安全性。方法 选取2018年 7月至2019年7月内蒙古自治区包头市肿瘤医院和内蒙古包钢医院诊治的50例复发弥漫大B细胞淋巴瘤患者作为研究对象，进行随机对照试验研究。依据随机数字表法分为观察组和对照组，每组25例。观察组接受来那度胺联合利妥昔单抗治疗，对照组接受利妥昔单抗+吉西他滨+奥沙利铂化疗（R-GEMOX方案）。比较2组患者治疗半年后的临床疗效、治疗1年内的生存率及治疗半年内的不良反应发生率。结果 观察组治疗后临床效果显著优于对照组，完全缓解和部分缓解率高于对照组［36.0%（9/25）比24.0%（6/25）；44.0%（11/25）比28.0%（7/25）］，差异均有统计学意义（χ2=10.550，P=0.001； χ2=4.590，P=0.032）。治疗1年内观察组生存率显著高于对照组，差异有统计学意义（χ2=7.279，P=0.007）。治疗半年内，观察组不良反应发生率低于对照组［12.0%（3/25）比56.0%（14/25）］，差异有统计学意义（χ2=10.784，P=0.002）。结论 来那度胺联合利妥昔单抗治疗老年复发弥漫大B细胞淋巴瘤效果优于R-GEMOX化疗方案，安全性较好。

• Objective To observe the effect and safety of lenalidomide combined with rituximab in the treatment of recurrent diffuse large B cell lymphoma in the elderly. Methods From July 2018 to July 2019, 50 elderly patients with recurrent diffuse large B cell lymphoma admitted to Baotou Cancer Hospital and Inner Mongolia Baogang Hospital were selected. They were randomly divided into observation group and control group, with 25 cases in each group. The observation group was treated by lenalidomide combined with rituximab, and the control group was treated by rituximab+gemcitabine+oxaliplatin chemotherapy. The clinical efficacy after half a year of treatment, survival rate within 1 year after treatment and incidence of adverse reactions within half a year after treatment were compared between the two groups. Results The clinical effect of the observation group after treatment was significantly better than that of the control group, the rates of complete remission and partial remission of the observation group were higher than those of the control group ［36.0%(9/25) vs 24.0%(6/25), 44.0%(11/25) vs 28.0%(7/25)］, and the differences were statistically significant (χ2=10.550, P=0.001; χ2=4.590, P=0.032). Within one year of treatment, the survival rate of the observation group was significantly higher than that of the control group(χ2=7.279, P=0.007). Within half a year, the incidence of adverse reactions in the observation group was lower than that in the control group［12.0%(3/25) vs 56.0%(14/25)］, and the difference was statistically significant(χ2=10.784, P=0.002). Conclusion Lenalidomide combined with rituximab is more effective and safer than R-GEMOX chemotherapy in the treatment of elderly patients with recurrent diffuse large B cell lymphoma.